SCHEMBL30765989

SCHEMBL30765989

COC(=O)Cn1c(-c2ccccc2)ncc(-c2ccccc2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2C9 P11712 1/20 0.48
GAA P10253 4/20 0.47
KMT2A Q03164 3/20 0.47
TSHR P16473 2/20 0.47
MEN1 O00255 1/20 0.47
GLA P06280 1/20 0.47
RCE1 Q9Y256 1/20 0.47
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
RAB9A P51151 1/20 0.44
CDK4 P11802 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765599 0.86 CTRC (0.54) KDM4ESMN1; SMN2ALDH1A1HSD17B10ELANE
SCHEMBL30765438 0.86 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1HSD17B10CYP1A2
SCHEMBL30765677 0.85 KDM4E (0.49) KDM4EALDH1A1HSD17B10CYP1A2CYP2C19
SCHEMBL30765727 0.80 KDM4E (0.44) KDM4ESMN1; SMN2ALDH1A1HSD17B10CYP1A2
SCHEMBL30765674 0.80 ALDH1A1 (0.42) KDM4ESMN1; SMN2ALDH1A1CYP1A2CYP2C19
SCHEMBL23461153 0.75 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1HSD17B10CYP1A2
SCHEMBL30765683 0.75 TUBB4A (0.47) KDM4ESMN1; SMN2ELANE
SCHEMBL30765492 0.75 ELANE (0.49) KDM4ESMN1; SMN2ELANE
SCHEMBL31618359 0.75 TSHR (0.48) KDM4ESMN1; SMN2ALDH1A1HSD17B10CYP1A2
SCHEMBL7965688 0.74 KDM4E (0.45) KDM4ESMN1; SMN2ALDH1A1HSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed